Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016237 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
A Phase 1 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00016237: Completed Phase 1 study, sponsored by EMD Serono.
NCT00016237 is a Phase 1 study that has completed, run by EMD Serono. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016237, a Phase 1 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 combined with a monoclonal antibody may be an effective treatment for kidney, bladder, or lung cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 combined with a monoclonal antibody in treating patients who have kidney, bladder, or lung cancer that has not responded to previous treatment.
Interventions
- BIOLOGICAL tucotuzumab celmoleukin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Phase | Phase 1 |
What the finished NCT00016237 record still lists
NCT00016237 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which tucotuzumab celmoleukin is the first listed.
NCT00016237 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00016237 about?
NCT00016237 is a clinical study titled "Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 combined with a monoclonal antibody may be an effective t...
What is the current status of trial NCT00016237?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-12.
What interventions are being tested in trial NCT00016237?
The interventions under investigation include: tucotuzumab celmoleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016237?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia